TMC-125 Tibotec

Curr Opin Investig Drugs. 2004 Feb;5(2):208-13.

Abstract

TMC-125, a non-nucleoside reverse transcriptase inhibitor, is being developed by Tibotec for the potential treatment of HIV infection. Phase IIa trials in treatment-naive and treatment-experienced HIV-1-infected individuals had been completed by February 2002. A long-term, phase IIb, dose-finding study in treatment-experienced patients started enroling patients in a number of European countries during 2002, and Canada during 2003.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic / statistics & numerical data
  • Drugs, Investigational / chemistry
  • Drugs, Investigational / pharmacokinetics
  • Drugs, Investigational / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • Humans
  • Nitriles
  • Pyridazines / chemistry
  • Pyridazines / pharmacokinetics
  • Pyridazines / therapeutic use*
  • Pyrimidines
  • Reverse Transcriptase Inhibitors / chemistry
  • Reverse Transcriptase Inhibitors / pharmacokinetics
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Technology, Pharmaceutical / methods

Substances

  • Drugs, Investigational
  • Nitriles
  • Pyridazines
  • Pyrimidines
  • Reverse Transcriptase Inhibitors
  • etravirine